Hepatitis C Articles (HCV)
Back
 
SVR in HIV/HCV Coinfected / DDIs
8 weeks -
A5327 Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-infected Individuals (SWIFT-C)
- (10/24/17)
EASL:
THERAPY WITH DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH HCV-RELATED LYMPHOPROLIFERATIVE DISORDERS AND MIXED CRYOGLOBULINEMIA
- (04/26/17)
EASL:
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study
- (04/20/17)
EASL:
Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study
- (04/18/16)
CROI:
GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS
- (02/20/17)
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies
- (12/08/15)
EASL:
Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination
- (04/21/16)
New HCV Drug Approvals - studies
- (09/22/17)
View Older Articles
Back to Top
www.natap.org